KUALA LUMPUR: AHAM Asset Management Berhad (“AHAM Capital” or “the Company”) proudly announces the launch of the AHAM World Series – Biotechnology Fund (“the Fund”). This new wholesale feeder growth fund offers investors diversified exposure to the rapidly advancing biotechnology sector.
The Fund’s strategy involves primarily investing in the Janus Henderson Horizon Biotechnology Fund (“Target Fund”), managed by Janus Henderson (“Target Fund Manager”). To achieve its objectives, the Fund will allocate at least 85% of its net asset value (NAV) to the Target Fund, with the remaining 15% potentially invested in money market instruments, deposits, and cash.
Anton Tan, Chief Officer of Product Solutions & Customer Experience at AHAM Capital, remarked, “Biotechnology companies lead scientific innovation, significantly advancing our understanding of genetics to develop new treatments for major diseases. Over the past decade, the number of FDA-approved drugs has more than doubled, from 121 to 243, demonstrating substantial scientific progress.
“Healthcare spending is set to rise due to demographic shifts in the US, aging populations, and globalization. These long-term trends create a favorable environment for biotechnology investments. Despite the sector’s recent downturn, it is now trading at a significant discount to the broader market, offering a unique ‘innovation on sale’ opportunity.
“The biotechnology sector encompasses a wide range of opportunities, from small to large-cap companies, providing diversification for investors’ portfolios. By investing in this healthcare revolution, investors can benefit from ongoing breakthroughs in biotechnology,” Anton added.
Andy Acker, Portfolio Manager of Janus Henderson, shared his insights on the sector’s outlook: “Biotechnology is experiencing unprecedented innovation, driven by advances in life science tools, genetic engineering, and new treatment modalities for diseases such as cancer, autoimmune disorders, and rare genetic conditions. These advancements present opportunities to identify the next blockbuster therapies and generate alpha for clients.
“However, success in biotech is highly binary, with a pronounced disparity between winners and losers. To mitigate this, the Janus Henderson biotechnology team combines investment experience, scientific expertise, and proprietary statistical models to estimate the success probability of drugs in clinical development. The team also considers perspectives from physicians, patients, and payers to evaluate the commercial prospects of new therapies, aiming to achieve the best investment outcomes for our clients.”
The Fund is ideal for sophisticated investors seeking capital appreciation with a medium to long-term investment horizon. The Fund’s base currency is USD, with three available currency classes: USD Class, MYR Class, and MYR Hedged-Class. The minimum investment amounts are $10,000 for the USD Class and $30,000 for the MYR Class and MYR Hedged-Class.
Investors are encouraged to read and understand the Fund’s Product Highlights Sheet and Information Memorandum dated 30 May 2024 before investing. For more information, visit aham.com.my.
